Vanda Pharmaceuticals, Inc. (VNDA)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$4.05+1.25%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put VNDA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Net loss improves toward -$49 million in Q1 2026: Net income: $-22.56M.
View ThesisRevenue growth is slowing — up about 8% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 59% in its worst 12-month stretch.
View RiskVanda’s growth case rests on launching BYSANTI and growing Fanapt sales, alongside late-stage clinical programs. Revenue growth rebounded to 24% year over year in Q3 2026 after falling 4% in Q2. Q3 earnings beat consensus, though the company remains unprofitable and its primary earnings pillar is under pressure. VNDA trades at 1.1× sales versus a 9.6× peer median, while expectations look modest versus our view. The 52% next-quarter miss probability adds risk to that growth case. Peer multiples imply a price about 89% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. VNDA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering VNDA (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare VNDA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| VNDA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put VNDA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Launch BYSANTI and grow Fanapt sales
Revenue target and approaching BYSANTI launch support growth plans, though the target is forward-looking.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Advance late-stage clinical programs and regulatory approvals
Positive trial results advance clinical development, though the headline lacks detail on trial stage and regulatory implications.
Threatens: Advance late-stage clinical programs and regulatory approvals
Phase 3 study failure impacts late-stage clinical program advancement.
Threatens: Advance late-stage clinical programs and regulatory approvals
Failed trial impacts late-stage clinical program advancement.
Advances: Advance late-stage clinical programs and regulatory approvals
Positive analyst sentiment supports late-stage clinical program advancements.
Advances: Advance late-stage clinical programs and regulatory approvals
Positive Phase III results support late-stage clinical programs.